Same pathway, new treatment for Rosacea

Rosacea is an interesting skin disease where there is treatment but no cure.  Also, successful treatment varies from patient to patient, therefore, it is important to discuss all options with a medical professional.  Current research into the inflammatory nature of rosacea shows dysregulation of the innate immune pathway.

Rosacea patients have increased levels of LL-37 (cathelicidin), which has been shown to increase cell inflammation.  Serine protease kallikrein-5 (KLK5) is thought to form or help expression of LL-37.  Current treatments influence different targets within the inflammatory pathway.  These researchers looked at the effects of ivermectin.  They are the first to show the effects of inhibition activity by ivermectin.

So what would happen if KLK5 activity is blocked by ivermectin?  How are other markers of inflammation affected when treatment inhibiting KLK5 is applied?  Read the full publication for all the details!

Séverine Thibaut de Ménonville et al.

Nestlé Skin Health R&D, Sophia Antipolis, France

Dermatology and Therapy. 2017;7(2):213-225.

Numerous intrinsic and extrinsic factors have been associated with the pathophysiology of rosacea, including dysregulation of innate immunity. A high level of cathelicidin antimicrobial peptides (e.g., LL-37) has been shown in the facial skin of patients with rosacea. Excessive production of both LL-37 and KLK5, the serine protease responsible for its cleavage, has been suggested to play a role in the pathophysiology of rosacea. Ivermectin 10 mg/g cream, indicated for the treatment of inflammatory lesions of rosacea, is reported to have dual anti-parasitic and anti-inflammatory properties. However, the exact mechanism of action of ivermectin cream in the treatment of rosacea is unknown.

Cytokines